GlassScriptPhysician profile
Amanda R Helm
NPI 1679931067
$3,588.48
in general payments reported to CMS, 2019-2025
39 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.86 · 2022: $617 · 2023: $978 · 2024: $869 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $408.82 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $345.52 | 2022-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $303.72 | 2022-2025 | |
| Abbvie INC. | $243.27 | 2021-2025 | |
| Amgen INC. | $215.80 | 2023-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $207.51 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $150.92 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $150.24 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Travere Therapeutics, INC. | $139.94 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $124.13 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.97 | 2022-2024 | Jardiance, Tradjenta |
| Pfizer INC. | $109.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $108.08 | 2022-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $103.27 | 2025 | Trintellix, Gattex, Entyvio |
| Daiichi Sankyo INC. | $91.67 | 2022-2024 | Injectafer |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.